Cell and Gene Therapy in Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, P

Cell and Gene Therapy in Parkinson's Disease Pipeline constitutes 18+ key companies continuously working towards developing 20+ Cell and Gene Therapy in Parkinson's Disease treatment therapies, analyzes DelveInsight.

Cell and Gene Therapy in Parkinson's Disease Overview:

According to the Parkinson's Foundation, Parkinson's disease is a neurodegenerative condition that primarily impacts dopamine-producing neurons in the substantia nigra region of the brain. As the disease progresses gradually, it is categorized into different stages to track symptom development and anticipate future changes. Typically, Parkinson's disease is classified into five stages: Stage I, Stage II, Stage III, Stage IV, and Stage V.

Request for a detailed insights report on Cell and Gene Therapy in Parkinson's Disease pipeline insights @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Cell and Gene Therapy in Parkinson's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cell and Gene Therapy in Parkinson's Disease Therapeutics Market.

Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Pipeline Report

DelveInsight's Cell and Gene Therapy in Parkinson's Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Cell and Gene Therapy in Parkinson's Disease treatment.
Key Cell and Gene Therapy in Parkinson's Disease companies such as Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences, and others are evaluating new drugs for Cell and Gene Therapy in Parkinson's Disease to improve the treatment landscape.
Promising Cell and Gene Therapy in Parkinson's Disease pipeline therapies in various stages of development include AB-1005, HB-adMSCs, ANPD 001, BRT-DA01, and others.

Recent breakthroughs in the Cell and Gene Therapy in Parkinson's Disease Pipeline Segment:

In May 2024, the FDA granted RMAT designation to bemdaneprocel, an investigational cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease. This designation underscores the therapy's potential to address unmet medical needs in treating Parkinson's.
Presented in March 2024, 18-month data from a Phase I trial demonstrated that bemdaneprocel was generally safe and well-tolerated in individuals with Parkinson's disease. The therapy involves transplanting stem cell-derived dopaminergic neuron progenitor cells into the brain's putamen, aiming to restore motor and non-motor functions.
In June 2024, the FDA approved iRegene's IND application for NouvNeu001, marking it as the first chemically induced allogeneic cell therapy for Parkinson's disease to enter clinical stages in the U.S. This approval allows iRegene to commence clinical trials to evaluate the therapy's safety and efficacy.

Cell and Gene Therapy in Parkinson's Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Cell and Gene Therapy in Parkinson's Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cell and Gene Therapy in Parkinson's Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cell and Gene Therapy in Parkinson's Disease market.

Download our free sample page report on Cell and Gene Therapy in Parkinson's Disease pipeline insights @ https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cell and Gene Therapy in Parkinson's Disease Emerging Drugs

AB-1005 : Asklepios BioPharmaceutical
HB-adMSCs: Hope Biosciences
ANPD 001: Aspen Neuroscience
BRT-DA01: BlueRock Therapeutics

Cell and Gene Therapy in Parkinson's Disease Companies

More than 18 key companies are currently working on developing cell and gene therapies for Parkinson's disease. Among them, Asklepios BioPharmaceutical and Hope Biosciences have drug candidates in the most advanced stage of development, specifically in Phase II clinical trials.

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Cell and Gene Therapy in Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Cell and Gene Therapy in Parkinson's Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Cell and Gene Therapy in Parkinson's Disease Therapies and Key Companies: Cell and Gene Therapy in Parkinson's Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cell and Gene Therapy in Parkinson's Disease Pipeline Therapeutic Assessment
• Cell and Gene Therapy in Parkinson's Disease Assessment by Product Type
• Cell and Gene Therapy in Parkinson's Disease By Stage
• Cell and Gene Therapy in Parkinson's Disease Assessment by Route of Administration
• Cell and Gene Therapy in Parkinson's Disease Assessment by Molecule Type

Download Cell and Gene Therapy in Parkinson's Disease Sample report to know in detail about the Cell and Gene Therapy in Parkinson's Disease treatment market @ Cell and Gene Therapy in Parkinson's Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Cell and Gene Therapy in Parkinson's Disease Current Treatment Patterns
4. Cell and Gene Therapy in Parkinson's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cell and Gene Therapy in Parkinson's Disease Late-Stage Products (Phase-III)
7. Cell and Gene Therapy in Parkinson's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cell and Gene Therapy in Parkinson's Disease Discontinued Products
13. Cell and Gene Therapy in Parkinson's Disease Product Profiles
14. Cell and Gene Therapy in Parkinson's Disease Key Companies
15. Cell and Gene Therapy in Parkinson's Disease Key Products
16. Dormant and Discontinued Products
17. Cell and Gene Therapy in Parkinson's Disease Unmet Needs
18. Cell and Gene Therapy in Parkinson's Disease Future Perspectives
19. Cell and Gene Therapy in Parkinson's Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Cell and Gene Therapy in Parkinson's Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.